1
|
Liu S, Bos NA, Verschuuren EAM, van Baarle D, Westra J. Biological Characteristics of HLA-G and Its Role in Solid Organ Transplantation. Front Immunol 2022; 13:902093. [PMID: 35769475 PMCID: PMC9234285 DOI: 10.3389/fimmu.2022.902093] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Accepted: 05/19/2022] [Indexed: 11/18/2022] Open
Abstract
Organ transplantation is a lifesaving option for patients with advanced diseases. Rejection is regarded as one of the most severe risk factors post-transplantation. A molecule that contributes to immune tolerance and resisting rejection is human leukocyte antigen (HLA)-G, which belongs to the non-classical major histocompatibility complex class (MHC) I family. HLA-G was originally found to play a role during pregnancy to maintain immune tolerance between mother and child. It is expressed in the placenta and detected in several body fluids as soluble factor as well as different membrane isoforms on cells. Recent findings on HLA-G show that it can also play multifaceted roles during transplantation. This review will explain the general characteristics and biological function of HLA-G and summarize the views supporting the tolerogenic and other roles of HLA-G to better understand its role in solid organ transplantation (SOT) and its complications. Finally, we will discuss potential future research on the role of HLA-G in prevention, diagnosis, and treatment in SOT.
Collapse
Affiliation(s)
- Siqi Liu
- Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Nicolaas A. Bos
- Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Erik A. M. Verschuuren
- Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Debbie van Baarle
- Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, Netherlands
| | - Johanna Westra
- Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
- *Correspondence: Johanna Westra,
| |
Collapse
|
2
|
Motofei IG. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. Expert Opin Drug Saf 2021; 21:599-612. [PMID: 34937484 DOI: 10.1080/14740338.2022.2020243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Immune checkpoint inhibitors (ICIs) are a revolutionary form of immunotherapy in cancer. However, the percentage of patients responding to therapy is relatively low, while adverse effects occur in a large number of patients. In addition, the therapeutic mechanisms of ICIs are not yet completely described. AREAS COVERED The initial view (articles published in PubMed, Scopus, Web of Science, etc.) was that ICIs increase tumor-specific immunity. Recent data (collected from the same databases) suggest that the ICIs pharmacotherapy actually extends beyond the topic of immune reactivity, including additional immune pathways, such as disrupting immunosuppression and increasing tumor-specific autoimmunity. Unfortunately, there is no clear delimitation between these specific autoimmune reactions that are therapeutically beneficial, and nonspecific autoimmune reactions/toxicity that can be extremely severe side effects. EXPERT OPINION Immune checkpoint mechanisms perform a non-selective immune regulation, maintaining a dynamic balance between immunosuppression and autoimmunity. By blocking these mechanisms, ICIs actually perform an immunological reset, decreasing immunosuppression and increasing tumor-specific immunity and predisposition to autoimmunity. The predisposition to autoimmunity induces both side effects and beneficial autoimmunity. Consequently, further studies are necessary to maximize the beneficial tumor-specific autoimmunity, while reducing the counterproductive effect of associated autoimmune toxicity.
Collapse
Affiliation(s)
- Ion G Motofei
- Department of Surgery/ Oncology, Carol Davila University, Bucharest, Romania.,Department of Surgery/ Oncology, St. Pantelimon Hospital, Bucharest, Romania
| |
Collapse
|
3
|
Tan B, Guo J, Wang L, Wang L, Gan X, Chen B. Expression and change of miR-199b-5p, s HLA-G in thyroid carcinoma. Exp Mol Pathol 2021; 120:104643. [PMID: 33932399 DOI: 10.1016/j.yexmp.2021.104643] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 04/11/2021] [Accepted: 04/26/2021] [Indexed: 11/28/2022]
Abstract
OBJECTIVE This research aims to investigate the relationship between the expression of microRNA-199b-5p (miR-199b-5p) and soluble human leukocyte antigen G (sHLA-G) in thyroid cancer tissues and its clinicopathological characteristics, as well as its impact on prognosis. METHODS Frozen tissues and serum from 85 patients with thyroid cancer, 27 with thyroid adenoma, 19 with Hashimoto's thyroiditis and 14 with nodular goiter from February 2014 to March 2016 were sampled. The miR-199b-5pmRNA expression in tissues was analyzed by real-time quantitative PCR. Serum HLA-G expression was detected by ELISA, and the relationship between s HLA-G expression and clinicopathological characteristics of thyroid cancer was analyzed. The relationship between 1- and 3-year survival rates of all patients and the expression of both detection indexes was observed. RESULTS Compared with normal thyroid specimens, nodular goiter, Hashimoto's thyroiditis, thyroid adenoma and thyroid cancer patients, the relative expression of miR-199b-5pmRNA in thyroid cancer tissues was the lowest, while that of s HLA-G was the highest in serum of patients (P < 0.05). The levels of miR-199b-5pmRNA and serum s HLA-G in tumor tissues were correlated with clinical pathological features such as tumor size, differentiation degree, capsule invasion, lymph node metastasis, etc. (all P < 0.05). The expression of miR-199b-5pmRNA and s HLA-G were negatively correlated. ROC curve identified that miR-199b-5pmRNA and HLA-g had obvious diagnostic value for thyroid cancer patients. Kaplan-Meier survival analysis manifested that the 1- and 3-year survival rates of the miR-199b-5p low expression group in thyroid cancer tissues were lower than the miR-199b-5p high expression group, and the rates of the s HLA-G low expression group were higher than the s HLA-G high expression group. CONCLUSION The miR-199b-5p expression in thyroid cancer tissues and HLA-g in serum were related to tumor size, differentiation degree, capsular invasion, lymph node metastasis and other characteristics. MiR-199b-5p may jointly affect the progression of thyroid cancer with s HLA-G.
Collapse
Affiliation(s)
- Beibei Tan
- Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan Province, China
| | - Jinglan Guo
- Department of Clinical laboratory, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
| | - Li Wang
- Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan Province, China
| | - Lisha Wang
- Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan Province, China
| | - Xilun Gan
- Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan Province, China
| | - Boxun Chen
- Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan Province, China.
| |
Collapse
|
4
|
Boujelbene N, Ben Yahia H, Babay W, Gadria S, Zemni I, Azaiez H, Dhouioui S, Zidi N, Mchiri R, Mrad K, Ouzari HI, Charfi L, Zidi I. HLA-G, HLA-E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma. HLA 2019; 94:11-24. [PMID: 30907063 DOI: 10.1111/tan.13536] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2018] [Revised: 03/19/2019] [Accepted: 03/21/2019] [Indexed: 12/13/2022]
Abstract
Little is known about non-classical HLA molecules in vulvar squamous cell carcinoma (VSCC). Because of the indoleamine-2,3-dioxygenase (IDO) immune tolerant role in association with HLA-G, we evaluated the clinical and prognostic value of HLA-G, HLA-E, and IDO in VSCC. HLA-G, HLA-E, and IDO expression was determined by immunohistochemistry in VSCC and associated with clinicopathological parameters and disease outcome. These three molecules were highly represented in tumoral tissues vs healthy matched vulvar tissues (P = 0.0001). Significant differences in HLA-G expression in stages, tumor size, tumor invasion depth, and resection margins subgroups were reported (P < 0.05). At 5 years, the cumulative survival rates was of 79.8% in patients with HLA-Glow expression vs 12.5% in those with HLA-Ghigh expression (P < 3 × 10-5 ). Similarly, patients with IDOhigh expression were at a significantly reduced overall survival (OS) and disease-free survival (DFS) rates (P = 0.011 and 0.045, respectively). The overexpression of the three molecules together worsen survival rates of VSCC patients (OS: P = 0.000038, DFS: P = 0.000085). Altogether, our results showed that HLA-G, HLA-E, and IDO may represent novel candidate markers for patients' prognosis and potential targets for VSCC therapy.
Collapse
Affiliation(s)
- Nadia Boujelbene
- Department of Pathology, Salah Azaïez Institute, Tunis, Tunisia
- Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia
| | - Hamza Ben Yahia
- Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia
| | - Wafa Babay
- Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia
| | - Selma Gadria
- Department of Surgical Oncology, Salah Azaïez Institute, Tunis, Tunisia
| | - Ines Zemni
- Department of Surgical Oncology, Salah Azaïez Institute, Tunis, Tunisia
| | - Houda Azaiez
- Department of Pathology, Salah Azaïez Institute, Tunis, Tunisia
| | - Sabrine Dhouioui
- Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia
| | - Nour Zidi
- Department of Radiotherapy, Salah Azaïez Institute, Tunis, Tunisia
| | - Rim Mchiri
- Department of Pathology, Salah Azaïez Institute, Tunis, Tunisia
| | - Karima Mrad
- Department of Pathology, Salah Azaïez Institute, Tunis, Tunisia
- Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia
| | - Hadda-Imene Ouzari
- Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia
| | - Lamia Charfi
- Department of Pathology, Salah Azaïez Institute, Tunis, Tunisia
| | - Inès Zidi
- Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia
| |
Collapse
|
5
|
Heidari MH, Movafagh A, Abdollahifar MA, Abdi S, Barez MM, Azimi H, Moradi A, Bagheri A, Heidari M, Hessam Mohseni J, Tadayon M, Mirsafian H, Ghatrehsamani M. Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker. Anat Cell Biol 2017; 50:69-72. [PMID: 28417057 PMCID: PMC5386928 DOI: 10.5115/acb.2017.50.1.69] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Revised: 02/18/2017] [Accepted: 02/22/2017] [Indexed: 12/25/2022] Open
Abstract
Prostate cancer is the most common cancer type in men and is the second cause of death, due to cancer, in patients over 50, after lung cancer. Prostate specific antigen (PSA) is a widely used tumor marker for prostate cancer. Recently, PSA is discovered in non-prostatic cancer tissues in men and women raising doubts about its specificity for prostatic tissues. PSA exists in low serum level in healthy men and in higher levels in many prostate disorders, including prostatitis and prostate cancer. Thus, a supplementary tumor marker is needed to accurately diagnose the cancer and to observe the patient after treatment. Recently, soluble human leukocyte antigen-G (sHLA-G) has been introduced as a new tumor marker for different cancer types, including colorectal, breast, lung, and ovary. The present descriptive-experimental study was carried out including patients with malignant prostate tumor, patients with benign prostate tumor, and a group of health men as the control group, as judged by an oncologist as well as a pathologist. After sterile blood sampling, sHLA-G was measured by enzyme-linked immunosorbent assay in each group. The data was then analyzed using one-way ANOVA. P≤0.05 was considered as statistically significant. The results showed that the mean of sHLA-G level was high in patients. Also, it was found that there was a significant difference in sHLA serum level between the three groups. The data revealed that sHLA-G can be a novel supplementary tumor marker in addition to PSA to diagnose prostate cancer.
Collapse
Affiliation(s)
- Mohammad Hassan Heidari
- Department of Anatomy and Biology, Faculty of Medicine, Shahid Beheshti University, Tehran, Iran.,Department of Anatomical Sciences and Biology, Proteomics Laboratory, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Abolfazl Movafagh
- Department of Medical Genetics, Cancer Research Center, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran
| | | | - Shabnam Abdi
- Department of Anatomical Sciences and Biology, School of Medicine, Azad University of Medical Sciences, Tehran, Iran
| | - Mohamadreza Mashhoudi Barez
- Department of Anatomical Sciences and Biology, Proteomics Laboratory, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Hadi Azimi
- Department of English Language Teaching, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Afshin Moradi
- Department of Pathology, Shohada Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran
| | - Amin Bagheri
- Cardiac Surgery and Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Matineh Heidari
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Maryam Tadayon
- Department of Education Region 1 Tehran (Shemiranat), Tehran, Iran
| | - Hoda Mirsafian
- Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
| | - Mahdi Ghatrehsamani
- Cellular and Molecular Biology Research Centre, Shahrekord University of Medical Sciences, Shahrekord, Iran
| |
Collapse
|
6
|
The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. J Immunol Res 2016; 2016:6829283. [PMID: 27999823 PMCID: PMC5141560 DOI: 10.1155/2016/6829283] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Revised: 09/16/2016] [Accepted: 10/12/2016] [Indexed: 12/21/2022] Open
Abstract
Malignant melanoma, a very common type of cancer, is a rapidly growing cancer of the skin with an increase in incidence among the Caucasian population. The disease is seen through all age groups and is very common in the younger age groups. Several studies have examined the risk factors and pathophysiological mechanisms of malignant melanoma, which have enlightened our understanding of the development of the disease, but we have still to fully understand the complex immunological interactions. The examination of the interaction between the human leucocyte antigen (HLA) system and prognostic outcome has shown interesting results, and a correlation between the down- or upregulation of these antigens and prognosis has been seen through many different types of cancer. In malignant melanoma, HLA class Ia has been seen to influence the effects of pharmaceutical drug treatment as well as the overall prognosis, and the HLA class Ib and regulatory T cells have been correlated with tumor progression. Although there is still no standardized immunological treatment worldwide, the interaction between the human leucocyte antigen (HLA) system and tumor progression seems to be a promising focus in the way of optimizing the treatment of malignant melanoma.
Collapse
|
7
|
Li T, Huang H, Liao D, Ling H, Su B, Cai M. WITHDRAWN: Lack of association between the HLA-G 3'UTR 14-bp ins/del polymorphism and cancer risk: A meta-analysis of case-control study. Hum Immunol 2015:S0198-8859(15)00564-9. [PMID: 26585360 DOI: 10.1016/j.humimm.2015.11.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2014] [Revised: 08/26/2014] [Accepted: 11/12/2015] [Indexed: 11/22/2022]
Abstract
This article hashas been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Collapse
Affiliation(s)
- Tao Li
- Department of Chemotherapy, People's Hospital of Gaozhou, Gaozhou, Guangdong, China.
| | - Haohai Huang
- School of Pharmacy, Guangdong Medical College, Dongguan, Guangdong, China
| | - Dan Liao
- Sino-American Cancer Research Institute, Guangdong Medical College, Dongguan, Guangdong, China
| | - Huahuang Ling
- Department of Chemotherapy, People's Hospital of Gaozhou, Gaozhou, Guangdong, China
| | - Bingguang Su
- Department of Chemotherapy, People's Hospital of Gaozhou, Gaozhou, Guangdong, China
| | - Maode Cai
- Department of Chemotherapy, People's Hospital of Gaozhou, Gaozhou, Guangdong, China
| |
Collapse
|
8
|
Gimenes F, Teixeira JJV, de Abreu ALP, Souza RP, Pereira MW, da Silva VRS, Bôer CG, Maria-Engler SS, Bonini MG, Borelli SD, Consolaro MEL. Human leukocyte antigen (HLA)-G and cervical cancer immunoediting: a candidate molecule for therapeutic intervention and prognostic biomarker? Biochim Biophys Acta Rev Cancer 2014; 1846:576-89. [PMID: 25453366 DOI: 10.1016/j.bbcan.2014.10.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 10/14/2014] [Accepted: 10/14/2014] [Indexed: 02/06/2023]
Abstract
While persistent infection with oncogenic types of human Papillomavirus (HPV) is required for cervical epithelial cell transformation and cervical carcinogenesis, HPV infection alone is not sufficient to induce tumorigenesis. Only a minor fraction of HPV infections produce high-grade lesions and cervical cancer, suggesting complex host-virus interactions. Based on its pronounced immunoinhibitory properties, human leukocyte antigen (HLA)-G has been proposed as a possible prognostic biomarker and therapeutic target relevant in a wide variety of cancers and viral infections, but to date remains underexplored in cervical cancer. Given the possible influence of HLA-G on the clinical course of HPV infection, cervical lesions and cancer progression, a better understanding of HLA-G involvement in cervical carcinogenesis might contribute to two aspects of fundamental importance: 1. Characterization of a novel diagnostic/prognostic biomarker to identify cervical cancer and to monitor disease stage, critical for patient screening; 2. Identification of HLA-G-driven immune mechanisms involved in lesion development and cancer progression, leading to the development of strategies for modulating HLA-G expression for treatment purposes. Thus, this systematic review explores the potential involvement of HLA-G protein expression and polymorphisms in cervical carcinogenesis.
Collapse
Affiliation(s)
- Fabrícia Gimenes
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil
| | - Jorge Juarez Vieira Teixeira
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil
| | - André Luelsdorf Pimenta de Abreu
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil
| | - Raquel Pantarotto Souza
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil
| | - Monalisa Wolski Pereira
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil
| | - Vânia Ramos Sela da Silva
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil
| | - Cinthia Gandolfi Bôer
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil
| | - Silvya Stuchi Maria-Engler
- Clinical Chemistry and Toxicology Department, School of Pharmaceutical Sciences, University of São Paulo, 05508000 São Paulo, Brazil
| | - Marcelo Gialluisi Bonini
- College of Medicine, Departments of Medicine, Pharmacology and Pathology, University of Illinois at Chicago, 60612 Chicago, IL, USA
| | - Sueli Donizete Borelli
- Laboratory of Immunogenetics, Department of Basic Health Sciences, State University of Maringá, 87020900 Paraná, Brazil
| | - Márcia Edilaine Lopes Consolaro
- Laboratory of Clinical Cytology, Department of Clinical Analysis and Biomedicine, State University of Maringá, 87020900 Paraná, Brazil.
| |
Collapse
|
9
|
Zheng J, Xu C, Chu D, Zhang X, Li J, Ji G, Hong L, Feng Q, Li X, Wu G, Du J, Zhao Q. Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis. Immunol Lett 2014; 161:13-9. [PMID: 24768599 DOI: 10.1016/j.imlet.2014.04.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Revised: 04/10/2014] [Accepted: 04/11/2014] [Indexed: 12/27/2022]
Abstract
Human leukocyte antigen G (HLA-G) is a non-classical HLA class I molecule thought to play a key role in maternal-fetal tolerance and cancer immune evasion. This study aimed to investigate the HLA-G expression in lesion sections and plasma sHLA-G levels of primary esophageal squamous cell carcinoma (ESCC) patients and its clinical significance in diagnosis and prognosis of ESCC. 60 ESCC patients and 28 healthy controls were recruited, and the positive expression of HLA-G in ESCC lesions and adjacent normal tissues were 70% (42/60) and 8.6% (5/60) (P<0.05), respectively, while no expression was found in normal controls. HLA-G1 and HLA-G5 were determined to be dominating isoforms measured by RT-PCR. There was a significant difference in plasma sHLA-G levels between patients with ESCC (15.04 U/ml, range 4.33-250.00 U/ml) and healthy controls (6.81 U/ml, range 0-29.27 U/ml) (P<0.01). The plasma IL-10 level was higher in ESCC patients than the controls (23.86 pg/ml vs. 12.81 pg/ml, P<0.01). HLA-G expression in lesion tissues was correlated with cancer cell differentiation (P=0.033), lymph node metastasis (P=0.035) of ESCC. However, no obvious correlations were demonstrated between the plasma sHLA-G levels and the clinicopathological parameters. There was a significant correlation between sHLA-G and IL-10 expression (r=0.353, P=0.006) in patients with Esophageal squamous cell carcinoma. HLA-G positive expression showed poorer prognosis of ESCC. HLA-G positive expression might serve as a potential marker in the diagnosis or prediction of ESCC.
Collapse
Affiliation(s)
- Jianyong Zheng
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Chunsheng Xu
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Dake Chu
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Xiaoying Zhang
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Jipeng Li
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Gang Ji
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Liu Hong
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Quanxin Feng
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Xiaohua Li
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Guosheng Wu
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Jianjun Du
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China
| | - Qingchuan Zhao
- State Key Laboratory of Cancer Biology, Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province 710032, China.
| |
Collapse
|
10
|
HLA-G5 in the blood of leukemia patients and healthy individuals. Leuk Res 2013; 37:139-45. [DOI: 10.1016/j.leukres.2012.10.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2012] [Revised: 10/15/2012] [Accepted: 10/21/2012] [Indexed: 12/18/2022]
|
11
|
Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 2012; 22:350-8. [PMID: 22465194 DOI: 10.1016/j.semcancer.2012.03.003] [Citation(s) in RCA: 127] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2012] [Accepted: 03/15/2012] [Indexed: 12/21/2022]
Abstract
In human tumors alterations in the surface expression and/or function of the major histocompatibility complex (MHC) class I antigens are frequently found and equip neoplastic cells with mechanisms to escape immune control. The aberrant expression of HLA class I molecules can be caused by structural alterations or dysregulations of genes encoding the classical HLA class I antigens and/or components of the HLA class I antigen processing machinery (APM). The dysregulation of APM components could occur at the epigenetic, transcriptional or post-transcriptional level. In some malignancies these abnormalities are significantly associated with a higher tumor staging, grading, disease progression and a reduced survival of patients as well as a failure to CD8(+) T cell-based immunotherapies. In addition to HLA class I abnormalities, expression of the non-classical HLA-G antigen is often induced in tumors, which could be mediated by various microenvironmental factors. Interestingly, soluble HLA-G serum and plasma levels have been useful markers for the prediction of some malignancies. The biological consequence of HLA-G expression or sHLA-G is an escape from T and NK cell-mediated recognition. Thus, alterations of non-classical and classical HLA class I antigens and components of the antigen processing pathway provide tumor cells with different mechanisms to inactivate immune responses resulting in tumor growth and evasion from host immune surveillance.
Collapse
Affiliation(s)
- Juergen Bukur
- Martin-Luther-University Halle-Wittenberg, Institute of Medical Immunology, Halle (Saale), Germany
| | | | | |
Collapse
|